Who Exports Fluoxetine from India — 253 Suppliers Behind a $235.3M Market
India's fluoxetine export market is supplied by 253 active exporters who collectively shipped $235.3M across 3,702 shipments. SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED leads with a 48.4% market share, followed by INTAS PHARMACEUTICALS LIMITED and MICRO LABS LIMITED. The top 5 suppliers together control 80.4% of total export value, reflecting a concentrated market structure.
Top Fluoxetine Exporters from India — Ranked by Export Value
SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED is the leading fluoxetine exporter from India, holding a 48.4% share of the $235.3M market across 3,702 shipments from 253 exporters. The top 5 suppliers — SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED, MICRO LABS LIMITED, AUROBINDO PHARMA LTD, TORRENT PHARMACEUTICALS LTD — collectively control 80.4% of total export value, indicating a highly concentrated market. Individual shares are: SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED (48.4%), INTAS PHARMACEUTICALS LIMITED (12.5%), MICRO LABS LIMITED (11.0%), AUROBINDO PHARMA LTD (4.6%), TORRENT PHARMACEUTICALS LTD (3.8%).
Top Fluoxetine Exporters from India
Ranked by export value · 253 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $113.8M | 1 | 48.4% |
| 2 | INTAS PHARMACEUTICALS LIMITED FLUOXETINE CAPSULES USP 20 MG -PH.DRU.& MED.: FLUOXETINE CAPSULES BP 20PH.DRU.& MED.: ACH FLUOXETINE 20MG CAPSU | $29.5M | 7 | 12.5% |
| 3 | MICRO LABS LIMITED FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE CAPSULES USP 20 MG -FLUOXETINE APOTEX 20MG CAPSULES | $25.9M | 16 | 11.0% |
| 4 | AUROBINDO PHARMA LTD FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE CAPSULES 20MG(FLUOXETINE ORIOFLUOXETINE TABLETS USP 10 MG | $10.9M | 5 | 4.6% |
| 5 | TORRENT PHARMACEUTICALS LTD FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $9.0M | 2 | 3.8% |
| 6 | ALEMBIC PHARMACEUTICALS LIMITED FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $5.8M | 2 | 2.5% |
| 7 | MARKSANS PHARMA LIMITED FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MG | $5.6M | 3 | 2.4% |
| 8 | DR.REDDY'S LABORATORIES LTD FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MG | $4.7M | 7 | 2.0% |
| 9 | APL HEALTHCARE LIMITED FLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MGFLUOXETINE CAPSULES 20MG | $3.6M | 1 | 1.5% |
| 10 | CIPLA LIMITED FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE BP 20MG CAPSULESFLUOXETINE BP 20 MG CAPSULES | $3.0M | 4 | 1.3% |
| 11 | MEDREICH LIMITED FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE BP 20MG CAPSULESFLUOXETINE BP 20 MG CAPSULES | $2.2M | 2 | 0.9% |
| 12 | MACLEODS PHARMACEUTICALS LTD | $1.8M | 5 | 0.8% |
| 13 | MEDOPHARM FLUOXETINE CAPSULES USP 20 MG -FLUOXETINE CAPSULES BP 20MG (5000 X 10 XFLUOXETINE CAPSULES USP 20 MG PCS | $1.5M | 4 | 0.6% |
| 14 | DR REDDY S LABORATORIES LIMITED FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE TABLETS USP 10 MGFLUOXETINE TABLETS USP 20 MG | $1.4M | 2 | 0.6% |
| 15 | AUROBINDO PHARMA LIMITED FLUOXETINE 20MG CAPSULES - TAX IFLUOXETINE CAPSULES 20MG(FLUOXETINE ORIOFLUOXETINE TABLETS USP 10 MG | $1.3M | 6 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Fluoxetine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter, December | Yes, April 2007 | Yes | Not verified | FDA inspection in December 2022 found data falsification at Sanand facility. |
| Aurobindo Pharma Limited | Warning Letter, May 2011 | Yes, March 2024 | Yes | Not verified | FDA issued a warning letter in May 2011 for Units III and VI. |
| Alembic Pharmaceuticals Limited | Approved | Yes | Yes | 223 | Received multiple FDA approvals between 2024 and 2025. |
| Dr. Reddy's Laboratories Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified for multiple facilities. |
| Cipla Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified for multiple facilities. |
| Macleods Pharmaceuticals Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified for multiple facilities. |
| Torrent Pharmaceuticals Limited | Approved | Yes | Yes | Not verified | WHO-GMP certified for multiple facilities. |
| APL Healthcare Limited | Approved | Yes, March 2024 | Yes | Not verified | WHO-GMP compliance accepted in March 2024. |
TransData Nexus reviewed the regulatory standing of 8 leading Fluoxetine exporters from India. 6 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Fluoxetine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as "Genome Valley," is a leading hub for pharmaceutical manufacturing and biotech research in India. The city hosts major companies like Dr. Reddy’s Laboratories and Aurobindo Pharma, which are involved in the production of active pharmaceutical ingredients (APIs) and finished formulations. Hyderabad's infrastructure supports large-scale manufacturing, making it a critical node in the supply chain for bulk drugs, including Fluoxetine.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical manufacturing capabilities, particularly in formulations. Companies like Alembic Pharmaceuticals, headquartered in Vadodara, have a significant presence in this region. Alembic Pharmaceuticals is known for producing a range of pharmaceutical products, including Fluoxetine. The region's well-established infrastructure and proximity to major ports facilitate efficient export operations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a powerhouse of the Indian pharmaceutical industry, contributing approximately 25-30% of the country's total pharmaceutical output. This region houses the headquarters of industry giants like Cipla and Sun Pharma, serving as a central hub for corporate functions, regulatory affairs, marketing, and R&D. Its strategic location and well-developed infrastructure make it a pivotal gateway for pharmaceutical exports, including Fluoxetine.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives and supportive government policies. This cluster hosts numerous pharmaceutical companies specializing in generic drugs and formulations. The region's cost-effective production capabilities make it an attractive location for manufacturing Fluoxetine and other pharmaceuticals.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of potential suppliers to ensure consistent quality and regulatory adherence.
- Leverage Export Hubs: Utilize the Mumbai-Thane-Raigad region's infrastructure for efficient export logistics, given its established role as an export gateway.
- Monitor Regulatory Changes: Stay informed about policy changes in tax incentive zones like Baddi-Nalagarh to capitalize on cost advantages.
By strategically sourcing from these clusters, TransData Nexus can optimize its supply chain for Fluoxetine, ensuring reliability, quality, and cost-effectiveness.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Fluoxetine exporters from India
Torrent Pharmaceuticals Ltd — Torrent Pharmaceuticals acquires Curatio Healthcare
In September 2022, Torrent Pharmaceuticals Ltd acquired Curatio Healthcare, a skincare manufacturer, for ₹2,000 crores. - IMPACT: This acquisition is expected to diversify Torrent's product portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Fluoxetine export operations.
Impact: This acquisition is expected to diversify Torrent's product portfolio, potentially influencing its strategic focus and resource allocation, which may indirectly affect its Fluoxetine export operations.
Aurobindo Pharma Ltd — Aurobindo Pharma acquires remaining stake in GLS Pharma
In early 2025, Aurobindo Pharma Ltd completed the acquisition of the remaining 49% stake in GLS Pharma, a Hyderabad-based oncology company, thereby gaining full ownership. - IMPACT: This consolidation enhances Aurobindo's oncology capabilities, potentially leading to a strategic shift that may impact its focus on Fluoxetine exports.
Impact: This consolidation enhances Aurobindo's oncology capabilities, potentially leading to a strategic shift that may impact its focus on Fluoxetine exports.
Torrent Pharmaceuticals Ltd — Aman Mehta appointed Managing Director of Torrent Pharma
On May 20, 2025, Aman Mehta was appointed as the Managing Director of Torrent Pharmaceuticals Ltd. - IMPACT: Leadership changes can influence company strategy and operations, potentially affecting Torrent's Fluoxetine export activities.
Impact: Leadership changes can influence company strategy and operations, potentially affecting Torrent's Fluoxetine export activities.
Common Questions — Fluoxetine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which fluoxetine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SIDMAK LABORATORIES (INDIA) PRIVATE LIMITED leads with 99 recorded shipments worth $113.8M. INTAS PHARMACEUTICALS LIMITED (97 shipments) and MICRO LABS LIMITED (154 shipments) are also established high-volume exporters.
Q How many fluoxetine manufacturers are there in India?
India has 253 active fluoxetine exporters with a combined export market of $235.3M across 3,702 shipments to 101 countries. The top 5 suppliers hold 80.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for fluoxetine from India?
Average FOB unit price: $18.42 per unit, ranging from $0.00 to $48554.14. Average shipment value: $63.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 253 verified Indian exporters of Fluoxetine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,702 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 101 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,702 Verified Shipments
253 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists